Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04629729 · ClinicalTrials.gov registry record · Phase 1
FT819 in Subjects With B-cell Malignancies
A Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, B-Cell, sponsored by Fate Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 18
- Study locations
NCT04629729: Active Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, B-Cell, sponsored by Fate Therapeutics.
NCT04629729 is a Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, B-Cell that is active but no longer recruiting, run by Fate Therapeutics. The registered enrollment target is 54 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (70% lower). The trial reports 18 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04629729, a Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, B-Cell, is active but no longer recruiting, sponsored by Fate Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG IL-2
- DRUG Bendamustine
- DRUG FT819
Study Locations (18)
California
- UC Davis - Davis
- Scripps Green Hospital - La Jolla
- UCLA Ronald Reagan Medical Center - Los Angeles
- Stanford Cancer Institute - Palo Alto
Florida
- University of Florida - Gainesville
- Mayo Florida - Jacksonville
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Arizona - Phoenix
Iowa
- University of Iowa - Iowa City
Kansas
- The University of Kansas Cancer Center - Westwood
Kentucky
- Norton Cancer Institute, St. Matthews Campus - Louisville
Minnesota
- Mayo Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-07-12 |
| Est. Completion | 2039-09-30 |
| Phase | Phase 1 |
What the registry record for NCT04629729 still lists
NCT04629729 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (70% lower).
The record links to 3 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04629729 lists 18 locations in 14 states (California, Florida, Alabama).
Frequently Asked Questions
What is clinical trial NCT04629729 about?
NCT04629729 is a clinical study titled "FT819 in Subjects With B-cell Malignancies". This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage whe...
What is the current status of trial NCT04629729?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2021-07-12. Estimated completion is 2039-09-30.
What conditions does trial NCT04629729 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Lymphoma, B-Cell, Precursor B-Cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT04629729?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), IL-2 (DRUG), Bendamustine (DRUG), FT819 (DRUG).
Who is sponsoring clinical trial NCT04629729?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04629729 being conducted?
This trial has 18 study locations across Alabama, Arizona, California, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04629729's enrollment target sits among peer trials
54 98th of 187 higher than 89 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI